<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Common Rheumatologic Diseases
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/common-rheumatologic-diseases" data-history-node-id="2587" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Common Rheumatologic Diseases
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Rheumatoid Arthritis – Greg Jackson
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Background
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Proliferation of synovial tissue, mediated by TNF, IL-1, IL-6 leading to joint destruction
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Chronic, inflammatory polyarthritis affecting the small joints of the hands, wrists, and feet
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Pain and swelling of joints, typically symmetric MCP, wrists, MTP affected
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Ulnar deviation, swan neck, boutonniere deformities are late manifestations of untreated disease
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Morning stiffness lasting >1 hr suggests inflammatory arthritis like RA, but is not specific
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                C1-C2 instability: pts need evaluation with imaging prior to surgical procedure/intubation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Evaluation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Clinical diagnosis and positive RF, anti-CCP (as described in labs section above), though up to 30% patients have seronegative RA , elevated ESR and CRP
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                CBC, CMP, HIV, Hepatitis B and C screening; Quantiferon Gold (for possible biologics)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Obtain hand films to assess for osteopenia & erosions
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Management
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                The majority of joint damage occurs early in the disease so early treatment paramount
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                DMARDs: start with MTX; if inadequate response, add biologic such as TNF inhibitors
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Dosing
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  : MTX 7.5-20 mg weekly; need to supplement with folic acid 1 mg daily
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Requires
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  routine lab monitoring for bone marrow suppression, lung and liver toxicity
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Contraception
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  must be used in women of childbearing age on MTX
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Symptomatic/Flare treatment (no impact on disease progression):
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  NSAIDs
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  : high doses required for anti-inflammatory effects (ie ibuprofen 3200 mg/day or 1000 mg/day naproxen), usually treat for 2 wks to achieve maximum analgesic effect
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Prednisone
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  5-10 mg/day for 2 weeks and then slow wean off or low-dose (5 mg or less)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p style="margin-top:1px">
        </p>
        <p style="margin-top:1px">
        </p>
       </div>
       <p>
       </p>
       <div class="WordSection2">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Anti-Phospholipid Syndrome – Gautam Babu
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Background
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Development of antiphospholipid antibodies (aPLs) = a heterogenous group of autoantibodies, which interact with endothelial cells through binding of
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style='font-family:"Cambria",serif'>
                β
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                2GPI receptor
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                APLs induce a procoagulant and proinflammatory endothelial phenotype, resulting in arterial, venous, or small vessel thromboembolic events and/or pregnancy losses
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Presentation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Common features: DVTs, thrombocytopenia, and livedo reticularis
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Arterial thromboses: renal, mesenteric, coronary and cerebral vasculature
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Pulmonary embolism, CTEPH, nonbacterial vegetations (Libman-Sacks endocarditis)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Evaluation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Revised Sapporo classification criteria are used to diagnose patients with APS
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                At least one of the clinical criteria and one of the laboratory criteria are met:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Vascular thrombosis (arterial, small vessel, or venous)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Pregnancy morbidity
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  LA (lupus anticoagulant) present, on 2 or more occasions at least 12 weeks apart
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  aCL (anticardiolipin antibody) of IgG and/or IgM isotype in serum or plasma, present in medium or high titer, on two or more occasions, at least 12 weeks apart
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Anti-beta-2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma, present on two or more occasions, at least 12 weeks apart
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <br/>
           </li>
          </ul>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <div class="WordSection3">
        <p>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Management
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Mainstay is anticoagulation for treatment and secondary prevention
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Do not use (ASA or AC) for primary thrombosis prevention
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Acute thromboembolism: Heparin gtt with bridge to warfarin
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Secondary thrombosis prevention, anticoagulation with warfarin is preferred
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Studies
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  suggest that DOACs are less effective than warfarin
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Goal INR 2-3 regardless of whether arterial or venous thromboembolism present
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                ASA 81 mg + warfarin for pts w/arterial events and risks for ASCVD
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-left:25px">
        </p>
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Systemic Lupus Erythematous
                 </span>
                </span>
               </span>
              </b>
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  – Greg Jackson
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Presentation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Characterized by multisystem inflammation, precise etiology of disease unknown
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Constitutional: fatigue, fevers, weight loss
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Neurologic: cerebritis, myelitis, psychosis
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Skin: malar rash, discoid rash, photosensitive rashes
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Hematologic: leukopenia, anemia, thrombocytopenia
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Pulmonary: pleuritis, pleural effusion, ILD
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Cardiac: pericarditis/myocarditis (also due to underlying inflammatory condition have increased risk for coronary artery disease, similar to RA); Libman-Sacks endocarditis
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Renal: nephritic/nephrotic syndrome
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                MSK: arthralgias/myalgias/arthritis
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Evaluation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                See section on rheumatology labs for specific sensitivity/specificity of tests
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                SLICC criteria not initially developed to diagnose SLE but often used:  need >/= 4/17 of SLICC criteria with >/=1 clinical and >/= 1 immunologic
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <br/>
         </li>
        </ul>
        <table align="center" class="TableGrid2" style="border-collapse:collapse; border:none">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Laboratory Criteria</td>
      <td>Laboratory Criteria</td>
    </tr>
    <tr>
      <td>Acute cutaneous rash (is Malar rash, etc.)</td>
      <td>Elevated ANA</td>
    </tr>
    <tr>
      <td>Chronic cutaneous Rash (i.e. Discoid rash, etc.)</td>
      <td>Elevated anti-dsDNA</td>
    </tr>
    <tr>
      <td>Alopecia, non-scarring</td>
      <td>Positive Anti-Sm</td>
    </tr>
    <tr>
      <td>Joint disease (Two or more joints with inflammatory characteristics)</td>
      <td>Positive Anti-phospholipid Screen</td>
    </tr>
    <tr>
      <td>Oral/nasal ulcers</td>
      <td>Low C3/C4</td>
    </tr>
    <tr>
      <td>Serositis (usually pleural or pericardial)</td>
      <td>NaN</td>
    </tr>
    <tr>
      <td>Neurologic (seizures, psychosis, AMS)</td>
      <td>NaN</td>
    </tr>
    <tr>
      <td>Anemia, leukopenia (&lt;1000), thrombocytopenia (&lt;100,000)</td>
      <td>NaN</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
        </p>
        <p>
         <span style="page:WordSection3">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Management
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Hydroxychloroquine mainstay of treatment, 200-400 mg/day, dose 5 mg/kg/day for long term to decrease risk of retinal toxicity
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Monitor
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  for retinal toxicity with yearly retinal exam
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Glucocorticoids for flares (Similar dosing to RA)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection3">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Usually
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  started with hydroxychloroquine and tapered once hydroxychloroquine has taken effect for symptom control
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection3">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Other immunosuppressive medications (MTX, MMF, AZA, RTX) used with rheumatology consultation: MMF, cyclophosphamide used in SLE with renal involvement
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <div class="WordSection4">
        <p>
        </p>
       </div>
       <p>
       </p>
       <div class="WordSection5">
       </div>
       <p>
       </p>
       <div class="WordSection6">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Catastrophic Anti-phospholipid Syndrome (CAPS) – Gautam Babu
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
         <span style="page:WordSection6">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Background
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Occurs in a small subset of patients with APS
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Rapid development of thromboses in multiple small blood vessels in various organs resulting in multiorgan failure
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection6">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Presentation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Similar presentation to APS, but multiple organs are involved in a short period of time
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Renal (hypertension, proteinuria, hematuria, acute renal failure), Pulmonary (ARDS, PE), Central Nervous System (encephalopathy, stroke, cerebral venous thrombosis), Cardiac (coronary thrombosis), and Cutaneous (livedo reticularis, acrocyanosis, purpura, ecchymosis, splinter hemorrhages, and necrosis resulting in ulceration)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Pts can develop systemic inflammatory response syndrome 2/2 extensive tissue damage
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <br/>
         </li>
        </ul>
        <p>
         <span style="page:WordSection6">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Evaluation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Exclude other causes of small vessel occlusion: HIT, DIC or TMA
                <b>
                </b>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Definite
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                diagnosis of CAPS is made when all four diagnostic criteria are present
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Diagnosis is
                <b>
                 probable
                </b>
                when a combination of these criteria is present
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection6">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Evidence
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  of involvement of three or more organs, systems, and/or tissues
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection6">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Development
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  of manifestations simultaneously or in less than a week
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection6">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Confirmation
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  by histopathology of small vessel occlusion in at least one organ or tissue
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection6">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Laboratory
                 </span>
                </span>
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  confirmation of the presence of antiphospholipid antibodies:
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta2-glycoprotein I
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection6">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Management
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Anticoagulation
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                : Heparin gtt acutely
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Transition
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                to warfarin:
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                If hemodynamically stable; no
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                bleeding or
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                recurrent thromboses
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Immunosuppression: methylprednisolone 0.5 to 1 g intravenously daily for 3 days, subsequently followed by oral prednisone therapy at 1 mg/kg/day
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Severe cases may require PLEX +/- IVIG
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection6">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Refractory CAPS may require rituximab or eculizumab
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <div class="WordSection7">
       </div>
       <p>
       </p>
       <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
        <p style="border:none; padding:0in">
         <span style="font-size:11pt">
          <span style="line-height:107%">
           <span style="font-family:Calibri,sans-serif">
            <b>
             <span style="font-size:12.0pt">
              <span style="line-height:107%">
               <span style="font-family:Palatino">
                Sarcoidosis – Jared Freitas
               </span>
              </span>
             </span>
            </b>
           </span>
          </span>
         </span>
        </p>
       </div>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Background
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Multisystem
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              disordered defined by forming noncaseating granulomas in different tissues
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Cardiac
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              and neuro manifestations can be isolated
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Presentation
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Constitutional
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              symptoms: fatigue, night sweats, weight loss, fevers, arthralgias, myalgias
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Pulmonary
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              symptoms (most common): dyspnea, cough, and wheezing
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Extrapulmonary
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              manifestations:
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Cutaneous
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 37.45pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Highly variable, but present in 25% of patients
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 37.45pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Papules, macules, plaques that can be isolated or in groups, commonly involving neck, upper back, extremities; in African Americans can leave scars and depigmented areas
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 37.45pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Lupus pernio: indurated, violaceous bumps on nose, lips, cheeks, ears
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:list 37.45pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Erythema nodosum
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Neuro
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Affects 5-10% pts; involving any part of CNS or PNS, causing CN, hypothalamic, seizures, myelopathy or radiculopathy, hydrocephalus, aseptic meningitis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Cardiac
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Granulomas can affect pericardium, myocardium and endocardium resulting in valvular disorders, conduction system and cardiomyopathy
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:list 28.1pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Liver/Spleen
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Granulomas in liver and spleen can lead to elevated LFTs, cirrhosis, anemia, leukopenia and thrombocytopenia (splenic sequestration)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:list 28.1pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Ocular
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Photophobia, red eye, pain, blurry vision
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Pts need eye exams to look for ocular involvement: uveitis (anterior and posterior), secondary glaucoma, retinal vasculitis, keratoconjunctivitis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Work Up
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Requires
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              combination of clinical presentation, radiographic manifestations, exclusion of other similarly presenting diseases, and noncaseating granulomas on pathology
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:list 28.1pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               CXR: hilar and mediastinal lymphadenopathy
              </span>
             </span>
             <span style="font-size:12.0pt">
              <span style='font-family:"Times New Roman",serif'>
               ±
              </span>
             </span>
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               pulmonary infiltrates
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:list 28.1pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               High-Resolution Chest CT
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Lymphadenopathy (bilateral and symmetric), with micro or macronodules, fibrotic changes (reticular opacities, traction bronchiectasis, volume loss)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:list 28.1pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               PFTs
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Typical findings: most sensitive is reduced DLCO, followed by reduced TLC, and then reduced VC (need to do full PFTs not just spirometry)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:list 28.1pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Labs:
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 CBC w/ diff, CMP, and urinalysis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 ACE level is of limited clinical use
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Testing for TB: Quant-Gold
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:list 28.1pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Biopsy
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Important to rule out mimics. The differential for “noncaseating granulomas” is extensive, including lymphoma and fungal infections
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Not required for pts w/ asymptomatic bilateral hilar adenopathy or
                 <b>
                  Lofgren syndrome
                 </b>
                 (fever, erythema nodosum, arthralgias, and bilateral hilar LAD)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 37.45pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Target accessible lesions, like skin lesions or lymph nodes. May need bronchoscopy
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
       </ul>
       <p style="margin-top:1px; margin-left:37px">
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             Management
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Most
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              pts do not require therapy
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Monitor symptoms, CXR, PFTs at 3-6 month intervals
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <b>
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Indications for treatment
              </span>
             </span>
            </b>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              : progressive disease or severe disease at presentation
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Mainstay of treatment is oral steroids:
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Dosing usually 0.3-0.6 mg/kg daily for 4-6 weeks
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:list 28.1pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 If only symptoms is cough, could consider inhaled glucocorticoids
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:12.0pt">
          <span style="line-height:107%">
           <span style="font-family:Palatino">
            If unresponsive or unable to tolerate steroids may require alternative agents (MTX, AZA)
           </span>
          </span>
         </span>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>